


Searching News Database: tetrahydrobiopterin
HSMN NewsFeed - 17 May 2023
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
HSMN NewsFeed - 3 Jun 2021
vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study
vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study
HSMN NewsFeed - 1 Jun 2020
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
HSMN NewsFeed - 29 Jan 2020
vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
HSMN NewsFeed - 1 Oct 2015
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
HSMN NewsFeed - 24 May 2007
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for Phenylketonuria (PKU)
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for Phenylketonuria (PKU)
HSMN NewsFeed - 16 Jan 2007
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
HSMN NewsFeed - 18 Dec 2006
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
Additional items found! 2
Members Archive contains
2 additional stories matching:
tetrahydrobiopterin
(Password required)
tetrahydrobiopterin
(Password required)
